Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATURN: Simeprevir + Daclatasvir + Ribavirin in Recurrent HCV Genotype 1b Post-Liver Transplant
NCT01938625Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2013
- Primary completion
- Apr 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of simeprevir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Started Dec 2013; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01938625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01938625.